Acurx Pharmaceuticals announces results of annual shareholder meeting; directors elected, auditor ratified

Acurx Pharmaceuticals, Inc.

Quorum of 67.29% of outstanding shares (10,648,350 of 15,823,102) was present at June 17, 2024 Annual Meeting.
Class III directors Robert J. DeLuccia, Joseph C. Scodari, James Donohue re-elected with broker non-votes of 4,836,213 each.
Ratification of CohnReznick LLP as independent auditor for FY2024 passed with 10,542,955 votes for, 69,261 against, 36,134 abstentions.
All director nominees received majority of votes cast excluding broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.